Share your views: Consultation on a proposal to control the derivatives and analogues of 4-piperidone and its salts under the Controlled Drugs and Substances Act

Current status: Closed

This consultation ran from October 28, 2023, to November 27, 2023.

On October 28, 2023, Health Canada published a Notice of Intent proposing to control the derivatives and analogues of 4-piperidone and its salts, a known fentanyl precursor, under the Controlled Drugs and Substances Act.

Under this proposal, the existing listing for 4-piperidone and its salts in Schedule VI to the Controlled Drugs and Substances Act and the Schedule to the Precursor Control Regulations would be expanded to include its derivatives and analogues, including 1-boc-4-piperidone, 3-methyl-4-piperidone, and 1-benzyl-4-piperidone. Evidence shows that these substances are being imported into Canada and/or detected in clandestine laboratories and being used to synthesize fentanyl and fentanyl analogues.

Who was the focus of this consultation

Health Canada consulted with:

• Licensed dealers of controlled substances and precursors;
• Law enforcement;
• Researchers working with controlled substances and precursors;
• Interested members of the public.

Related information

• Controlled Substances and Precursor Chemicals
• Controlled Drugs and Substances Act
• Precursor Control Regulations

Contact us

Office of Legislative and Regulatory Affairs
Controlled Substances Directorate
Health Canada
Email: csd.regulatory.policy-politique.reglementaire.dsc@hc-sc.gc.ca